DrugPatentWatch Database Preview
Celgene Company Profile
» See Plans and Pricing
What is the competitive landscape for CELGENE, and what generic alternatives to CELGENE drugs are available?
CELGENE has eight approved drugs.
There are forty-two US patents protecting CELGENE drugs.
There are six hundred and eleven patent family members on CELGENE drugs in forty-nine countries and twenty-one supplementary protection certificates in twelve countries.
Summary for Celgene
International Patents: | 611 |
US Patents: | 42 |
Tradenames: | 8 |
Ingredients: | 7 |
NDAs: | 8 |
Patent Litigation for Celgene: | See patent lawsuits for Celgene |
PTAB Cases with Celgene as patent owner: | See PTAB cases with Celgene as patent owner |
Drugs and US Patents for Celgene
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-002 | Feb 8, 2013 | AB | RX | Yes | No | 8,735,428*PED | Start Trial | Y | Start Trial | ||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | RX | Yes | No | 8,648,095 | Start Trial | Start Trial | ||||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | RX | Yes | No | 9,393,238 | Start Trial | Start Trial | ||||
Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-001 | Jul 16, 1998 | RX | Yes | No | 6,561,977 | Start Trial | Start Trial | ||||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-004 | Jun 29, 2006 | RX | Yes | Yes | 6,755,784 | Start Trial | Start Trial | ||||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-004 | Jun 29, 2006 | RX | Yes | Yes | Start Trial | Start Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Celgene
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | 7,435,745 | Start Trial |
Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-004 | Feb 8, 2013 | 8,158,653 | Start Trial |
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-002 | Dec 27, 2005 | 6,555,554 | Start Trial |
Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 6,315,720 | Start Trial |
Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | 7,723,361 | Start Trial |
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | 8,315,886 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CELGENE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2017-02-08 |
➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
International Patents for Celgene Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Slovenia | 2291080 | Start Trial |
Nicaragua | 201600022 | Start Trial |
European Patent Office | 2913326 | Start Trial |
Costa Rica | 10582 | Start Trial |
Japan | 2017132817 | Start Trial |
Mexico | 358940 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celgene Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2291080 | 2020C/539 | Belgium | Start Trial | PRODUCT NAME: OZANIMOD OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORHYDRATE D'OZANIMOD; AUTHORISATION NUMBER AND DATE: EU/1/20/1442 20200525 |
0688211 | 08C0036 | France | Start Trial | PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416 |
2291080 | LUC00177 | Luxembourg | Start Trial | PRODUCT NAME: OZANIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR OZANIMOD HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/20/1442 20200525 |
2105135 | 1590004-6 | Sweden | Start Trial | PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808 |
0688211 | C300358 | Netherlands | Start Trial | PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416 |
2105135 | 00140 | Estonia | Start Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.